Advertisement

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Thomas O'Hare, Matthew S. Zabriskie, Christopher A. Eide, Anupriya Agarwal, Lauren T. Adrian, Huihong You, Amie S. Corbin, Fei Yang, Richard D. Press, Victor M. Rivera, Julie Toplin, Stephane Wong, Michael W. Deininger and Brian J. Druker

Article Information

Citation 
vol. 118 no. 19 5250-5254
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 7, 2011
  • Accepted August 18, 2011
  • Published online November 10, 2011.

Article Versions


Contributors 
  • Thomas O'Hare, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2Howard Hughes Medical Institute, Portland, OR; 3Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;
  • Matthew S. Zabriskie, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2Howard Hughes Medical Institute, Portland, OR;
  • Christopher A. Eide, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2Howard Hughes Medical Institute, Portland, OR;
  • Anupriya Agarwal, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;
  • Lauren T. Adrian, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2Howard Hughes Medical Institute, Portland, OR;
  • Huihong You, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;
  • Amie S. Corbin, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;
  • Fei Yang, 4Department of Pathology, Oregon Health & Science University, Portland, OR;
  • Richard D. Press, 4Department of Pathology, Oregon Health & Science University, Portland, OR;
  • Victor M. Rivera, 5ARIAD Pharmaceuticals, Inc, Cambridge, MA; and
  • Julie Toplin, 6MolecularMD Corporation, Portland, OR
  • Stephane Wong, 6MolecularMD Corporation, Portland, OR
  • Michael W. Deininger, 3Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;
  • Brian J. Druker, 1Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR; 2Howard Hughes Medical Institute, Portland, OR;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output